Abstract
The 2014 Cancer Genome Atlas Research Network study provided a significant update to the molecular understanding of urothelial carcinoma pathogenesis, recognizing four molecular subgroups of urothelial carcinoma: Cluster I (previously “luminal-type”), Cluster II (previously “p53-like”), and Clusters III and IV (previously “basal-type”). Cluster I encompasses low-grade urothelial carcinomas with papillary architecture and FGFR3 mutations, arising from the historical hyperplasia pathway. Cluster II encompasses high-grade urothelial carcinomas (HGUC) with a predominantly flat growth pattern and a high potential for muscle invasion, arising from the historical dysplasia pathway. Clusters III and IV are high-grade urothelial carcinomas with squamous or sarcomatoid morphology. The main goal of urinary tract cytology is the detection of urothelial neoplasms that have a high risk for invasion and metastasis; therefore, the main focus of The Paris System for Reporting Urinary Cytology is the detection of clinically significant urothelial neoplasia, namely HGUC.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Sundling KE, Kurtycz DFI. Standardized terminology systems in cytopathology. Diagn Cytopathol. 2019;47(1):53–63. https://doi.org/10.1002/dc.24103.
Lammers RJM, Witjes WPJ, Hendricksen K, Caris CTM, Janzing-Pastors MHC, Witjes JA. Smoking status is a risk factor for recurrence after transurethral resection of non-muscle-invasive bladder cancer. Eur Urol. 2011;60(4):713–20. https://doi.org/10.1016/j.eururo.2011.07.010.
Koutros S, Rao N, Moore LE, et al. Targeted deep sequencing of bladder tumors reveals novel associations between cancer gene mutations and mutational signatures with major risk factors. Clin Cancer Res. Published online April 13,. 2021; https://doi.org/10.1158/1078-0432.CCR-20-4419.
Fischer EG. Nuclear morphology and the biology of cancer cells. Acta Cytol. 2020;64(6):511–9. https://doi.org/10.1159/000508780.
Koss LG. Bladder cancer from a perspective of 40 years. J Cell Biochem Suppl. 1992;16I:23–9. https://doi.org/10.1002/jcb.240501305.
Spruck CH, Ohneseit PF, Gonzalez-Zulueta M, et al. Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res. 1994;54(3):784–8.
Lopez-Beltran A, Cimadamore A, Montironi R, Cheng L. Molecular pathology of urothelial carcinoma. Hum Pathol. 2021;113:67–83. https://doi.org/10.1016/j.humpath.2021.04.001.
The Cancer Genome Atlas Research Network, Analysis Working Group: The University of Texas MD Anderson Cancer Center. Comprehensive molecular characterization of urothelial bladder carcinoma. Nature. 2014;507(7492):315–22. https://doi.org/10.1038/nature12965.
Kamoun A, de Reyniès A, Allory Y, et al. A consensus molecular classification of muscle-invasive bladder cancer. Eur Urol. 2020;77(4):420–33. https://doi.org/10.1016/j.eururo.2019.09.006.
Vollmer RT. A review of outcomes for stage Ta bladder tumors. Am J Clin Pathol. 2016;146(2):215–20. https://doi.org/10.1093/ajcp/aqw103.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2022 Springer Nature Switzerland AG
About this chapter
Cite this chapter
Sundling, K.E., Antic, T., Pambuccian, S.E. (2022). Pathogenesis of Urothelial Carcinoma. In: Wojcik, E.M., Kurtycz, D.F., Rosenthal, D.L. (eds) The Paris System for Reporting Urinary Cytology. Springer, Cham. https://doi.org/10.1007/978-3-030-88686-8_1
Download citation
DOI: https://doi.org/10.1007/978-3-030-88686-8_1
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-030-88685-1
Online ISBN: 978-3-030-88686-8
eBook Packages: MedicineMedicine (R0)